Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammation. Meanwhile, Retension Pharmaceuticals will use its IPO cash for mid-stage testing of a next-generation hypertension drug.
The post TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance appeared first on MedCity News.
